The Impact of Public Policy on Equitable Access to Technology for Children and Youth Living with Type 1 Diabetes in British Columbia, Canada.

IF 5.7 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Jeffrey Bone, Courtney Leach, Ananta Addala, Shazhan Amed
{"title":"The Impact of Public Policy on Equitable Access to Technology for Children and Youth Living with Type 1 Diabetes in British Columbia, Canada.","authors":"Jeffrey Bone, Courtney Leach, Ananta Addala, Shazhan Amed","doi":"10.1089/dia.2024.0366","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Objective:</i></b> Structural inequities impede technology uptake in marginalized populations living with type 1 diabetes (T1D). Our objective was to describe hemoglobin A1c (HbA<sub>1c</sub>), time in range (TIR), and pump use to evaluate the impact of a universal funding policy for continuous glucose monitoring (CGM) across levels of deprivation in children with T1D in the Canadian province of British Columbia (BC). <b><i>Methods:</i></b> Patients with T1D and at least one outpatient visit after June 10, 2020 (1-year before universal CGM funding) who were enrolled in the BC Pediatric Diabetes Registry were included (<i>n</i> = 477). The Canadian Index of Multiple Deprivation (quintile 1 = least deprived; quintile 5 = most deprived) was determined using postal code. Mixed effects models were used to describe HbA<sub>1c</sub>, TIR, and pump use, and an interrupted time series generalized additive model estimated the change in CGM use pre- and postintroduction of universal coverage. <b><i>Results:</i></b> No differences were observed among the five levels of deprivation for HbA<sub>1c</sub> and TIR; however, for residential instability, those with the highest level of deprivation had a lower probability of pump use (-18.9%, 95% confidence interval [CI] = -26.1% to -11.7% for quintile 5 vs. 1). There was an increase in CGM uptake across all levels of deprivation 1-year after introduction of universal CGM funding. For example, the difference in sensor use from the most to least deprived situational group was -21.0% (-35.4%, -6.6%) at the time of universal coverage and shrank to -4.6% (-21.6%, 12.4%) after 12 months of coverage. However, an equity gap in CGM use persisted between the least and most deprived groups (-21.9, 95% CI = -34.5 to -9.4 for quintile 5 vs. 1 in economic dependency). <b><i>Conclusions:</i></b> Universal coverage of CGM improved uptake; however, equity gaps persisted. More research is needed to explore nonfinancial barriers to diabetes technology use in marginalized populations.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/dia.2024.0366","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Structural inequities impede technology uptake in marginalized populations living with type 1 diabetes (T1D). Our objective was to describe hemoglobin A1c (HbA1c), time in range (TIR), and pump use to evaluate the impact of a universal funding policy for continuous glucose monitoring (CGM) across levels of deprivation in children with T1D in the Canadian province of British Columbia (BC). Methods: Patients with T1D and at least one outpatient visit after June 10, 2020 (1-year before universal CGM funding) who were enrolled in the BC Pediatric Diabetes Registry were included (n = 477). The Canadian Index of Multiple Deprivation (quintile 1 = least deprived; quintile 5 = most deprived) was determined using postal code. Mixed effects models were used to describe HbA1c, TIR, and pump use, and an interrupted time series generalized additive model estimated the change in CGM use pre- and postintroduction of universal coverage. Results: No differences were observed among the five levels of deprivation for HbA1c and TIR; however, for residential instability, those with the highest level of deprivation had a lower probability of pump use (-18.9%, 95% confidence interval [CI] = -26.1% to -11.7% for quintile 5 vs. 1). There was an increase in CGM uptake across all levels of deprivation 1-year after introduction of universal CGM funding. For example, the difference in sensor use from the most to least deprived situational group was -21.0% (-35.4%, -6.6%) at the time of universal coverage and shrank to -4.6% (-21.6%, 12.4%) after 12 months of coverage. However, an equity gap in CGM use persisted between the least and most deprived groups (-21.9, 95% CI = -34.5 to -9.4 for quintile 5 vs. 1 in economic dependency). Conclusions: Universal coverage of CGM improved uptake; however, equity gaps persisted. More research is needed to explore nonfinancial barriers to diabetes technology use in marginalized populations.

公共政策对加拿大不列颠哥伦比亚省 1 型糖尿病儿童和青少年公平获得技术的影响》(The Impact of Public Policy on Equitable Access to Technology for Children and Youth Living with Type 1 Diabetes in British Columbia, Canada)。
目的:结构性不平等阻碍了 1 型糖尿病(T1D)边缘化人群对技术的吸收。我们的目标是描述血红蛋白 A1c (HbA1c)、在量程内的时间 (TIR) 和血糖泵的使用情况,以评估加拿大不列颠哥伦比亚省 (BC) 不同贫困程度的 T1D 儿童持续葡萄糖监测 (CGM) 普及资助政策的影响。方法:纳入 2020 年 6 月 10 日(CGM 普及资助前 1 年)后在不列颠哥伦比亚省儿童糖尿病登记处登记并至少接受过一次门诊就诊的 T1D 患者(n = 477)。使用邮政编码确定加拿大多重贫困指数(五分位数 1 = 最贫困;五分位数 5 = 最贫困)。混合效应模型用于描述 HbA1c、TIR 和泵的使用情况,间断时间序列广义加法模型用于估算 CGM 使用情况在引入全民医保前后的变化。结果显示就 HbA1c 和 TIR 而言,五个贫困等级之间未观察到差异;但就居住不稳定性而言,贫困等级最高的人群使用泵的概率较低(-18.9%,95% 置信区间 [CI] = -26.1% 至 -11.7%,五分位数 5 与五分位数 1 相比)。在引入全民 CGM 资助 1 年后,所有贫困水平的 CGM 使用率都有所提高。例如,从最贫困组到最不贫困组,传感器使用率的差异在全民覆盖时为-21.0%(-35.4%,-6.6%),而在覆盖 12 个月后缩小至-4.6%(-21.6%,12.4%)。然而,在最贫困群体和最贫困群体之间,CGM 使用率的公平差距依然存在(在经济依赖性方面,五分位数 5 与五分位数 1 之间的差距为 -21.9,95% CI = -34.5 至 -9.4)。结论:CGM 的普及提高了接受率,但公平差距依然存在。需要开展更多的研究,探讨边缘化人群使用糖尿病技术的非经济障碍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes technology & therapeutics
Diabetes technology & therapeutics 医学-内分泌学与代谢
CiteScore
10.60
自引率
14.80%
发文量
145
审稿时长
3-8 weeks
期刊介绍: Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信